Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
p38 mitogen-activated protein kinase (MAPK) inhibitors act on stress-activated kinases of the MAPK family. In 1994 p38 was described as a kinase phosphorylated on tyrosine after exposure of cells to bacterial endotoxin or hyperosmolarity. In the same year, a kinase targeted by pyridinyl imidazole compounds was shown to regulate the biosynthesis of inflammatory cytokines. Adezmapimod, also known as SB 203580, and SB 202190 belong to this pyridinyl imidazole class and inhibit p38α and p38β. Doramapimod binds an allosteric pocket that becomes accessible in an inactive conformation of the kinase, a binding mode reported in 2002. PH-797804 and ralimetinib dimesylate are further p38α inhibitors for studies of inflammatory and stress signaling.
Asperosaponin V is an indirect modulator of key signaling pathways, including PI3K/AKT, BMP-2/p38, and ERK 1/2. This compound stimulates the proliferation of marrow stromal cells and promotes differentiation into osteoblasts, making it valuable for studying bone metabolism. Asperosaponin V holds potential for applications in osteoporosis research and fracture healing studies.
Out of stock
All 3 sizes
2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 signaling pathway and p38 MAPK pathway, known for its ability to decrease reactive oxygen species and fat accumulation in Caenorhabditis elegans. This compound enhances β-oxidation while suppressing fatty acid synthesis via upregulation of SKN-1/NRF2 and downregulation of SREBP-1c transcription factors. 2-HIBA exhibits notable anti-aging and lipid-lowering properties, making it valuable for investigating metabolic diseases, including obesity and diabetes. Additionally, it serves as a renewable precursor for methacrylate production through 2-HIB-CoA mutase-mediated biosynthesis.
